G
Durham clinical-stage biotech developing tumor-specific therapeutic antibodies isolated from single human B cells.
At a glance
- HQ: Durham
- Sector: Biotech
- Affiliation: Duke
See the full company record.
Founders, funding history and recent signals. Free accounts open immediately.
Sourced company notes 3 topics
Notes on Grid Therapeutics · last checked Oct 7, 2026
Overview
Clinical-stage biotechnology company in Durham, North Carolina, developing tumor-specific therapeutic antibodies for multiple cancer types, discovered directly from single human B cells.
Science
The lead antibody, GT103, was identified in patients with early-stage lung cancer whose disease did not progress to metastasis, and isolated from their B cells with molecular genomic techniques.
Duke
Co-founder and CEO Edward F. Patz Jr. signed an exclusive license with Duke University in August 2017 to develop the antibodies as targeted cancer immunotherapy; Duke became a shareholder in the company.
Listed roles
All Triangle rolesChecking listed roles…